Epithelioid sarcoma: the decisions you may face

Cancer page →Second-opinion finder →

2 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Early / localised

Localised

3 options

Wide resection with negative margins plus radiotherapy for large, deep or close-margin tumours; lymph node assessment considered because of nodal spread.

Guideline

NCCN · Category 2A

The options, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

IMRT / IGRT (modern external beam)Standard of care

IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.

Conformal dose, fewer side effects
Hypofractionation saves visits

Sentinel lymph node biopsyStandard of care

Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.

Avoids lymphoedema from full dissection

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

IMRT / IGRT (modern external beam)

Low-dose bath to normal tissue
Motion management

Sentinel lymph node biopsy

False negatives in ~5-10%

Questions to ask about this decision

Between Limb-salvage surgery and endoprosthetic reconstruction, IMRT / IGRT (modern external beam) and Sentinel lymph node biopsy, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma; ESMO-EURACAN-GENTURIS sarcoma guideline), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (localised), which of the standard options do you recommend and why?
Why: Guideline options include: Wide resection with negative margins plus radiotherapy for large, deep or close-margin tumours; lymph node assessment considered because of nodal spread.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

Advanced or metastatic

3 optionsCompare side by side →

Anthracycline-based chemotherapy; tazemetostat (accelerated approval 2020, EZH-202) was withdrawn from all markets in March 2026 after SYMPHONY-1 showed excess secondary blood cancers, so the EZH2 option is gone; clinical trial enrolment encouraged.

Guideline

NCCN · Category 2A

The options, in plain words

TazemetostatWithdrawnSmall-molecule EZH2 inhibitor

Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.

DoxorubicinApprovedCytotoxic chemotherapy (anthracycline)

The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.

IfosfamideApprovedCytotoxic chemotherapy (alkylating agent)

Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Doxorubicin all recorded rates →

Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.

Questions to ask about this decision

Between Tazemetostat, Doxorubicin and Ifosfamide, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (advanced or metastatic), which of the standard options do you recommend and why?
Why: Guideline options include: Anthracycline-based chemotherapy; tazemetostat (accelerated approval 2020, EZH-202) was withdrawn from all markets in March 2026 after SYMPHONY-1 showed excess secondary blood cancers, so the EZH2 option is gone; clinical trial enrolment encouraged.
Am I a candidate for Tazemetostat, Doxorubicin, Ifosfamide, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Epithelioid sarcoma: the decisions you may face

Cancer page →Second-opinion finder →

Early / localised

Localised

3 options

Wide resection with negative margins plus radiotherapy for large, deep or close-margin tumours; lymph node assessment considered because of nodal spread.

Guideline

NCCN · Category 2A

The options, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

IMRT / IGRT (modern external beam)Standard of care

Conformal dose, fewer side effects
Hypofractionation saves visits

Sentinel lymph node biopsyStandard of care

Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.

Avoids lymphoedema from full dissection

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

IMRT / IGRT (modern external beam)

Low-dose bath to normal tissue
Motion management

Sentinel lymph node biopsy

False negatives in ~5-10%

Questions to ask about this decision

Between Limb-salvage surgery and endoprosthetic reconstruction, IMRT / IGRT (modern external beam) and Sentinel lymph node biopsy, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma; ESMO-EURACAN-GENTURIS sarcoma guideline), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (localised), which of the standard options do you recommend and why?
Why: Guideline options include: Wide resection with negative margins plus radiotherapy for large, deep or close-margin tumours; lymph node assessment considered because of nodal spread.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

Advanced or metastatic

3 optionsCompare side by side →

Guideline

NCCN · Category 2A

The options, in plain words

TazemetostatWithdrawnSmall-molecule EZH2 inhibitor

Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.

DoxorubicinApprovedCytotoxic chemotherapy (anthracycline)

The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.

IfosfamideApprovedCytotoxic chemotherapy (alkylating agent)

Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Doxorubicin all recorded rates →

Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.

Questions to ask about this decision

Between Tazemetostat, Doxorubicin and Ifosfamide, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (advanced or metastatic), which of the standard options do you recommend and why?
Why: Guideline options include: Anthracycline-based chemotherapy; tazemetostat (accelerated approval 2020, EZH-202) was withdrawn from all markets in March 2026 after SYMPHONY-1 showed excess secondary blood cancers, so the EZH2 option is gone; clinical trial enrolment encouraged.
Am I a candidate for Tazemetostat, Doxorubicin, Ifosfamide, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.